Acrivon Therapeutics, Inc. Common Stock (ACRV)
USD 1.5
(-7.41%)
USD 1.5
(-7.41%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Operating Cash Flow | -42.64 Million | -30.11 Million | -13.98 Million | -2.8 Million |
| Net Income | -60.38 Million | -31.16 Million | -16.24 Million | -5.3 Million |
| Depreciation & Amortization | 536 Thousand | 364 Thousand | 37 Thousand | 13 Thousand |
| Deferred income taxes | -3.6 Million | - | 255 Thousand | 71 Thousand |
| Stock-based compensation | 11.61 Million | 2.18 Million | 497 Thousand | 3000.00 |
| Change in working capital | 8.13 Million | -1.53 Million | 328 Thousand | 317 Thousand |
| Other non-cash items | 1.06 Million | 33 Thousand | 1.14 Million | 2.09 Million |
| Investing Cash Flow | 50.71 Million | -141.67 Million | -238 Thousand | -15 Thousand |
| Investments in PPE | -1.28 Million | -2.16 Million | -238 Thousand | -15 Thousand |
| Acquisitions | - | - | - | - |
| Investment purchases | -56.52 Million | -150.17 Million | - | - |
| Sales/Maturities of investments | 108.53 Million | 10.66 Million | - | - |
| Other Investing Activities | - | - | - | - |
| Financing Cash Flow | -1.55 Million | 101.7 Million | 112.22 Million | 2.88 Million |
| Debt repayment | - | - | - | -58 Thousand |
| Dividends payments | - | - | - | - |
| Common Stock Repurchased | - | - | - | - |
| Common Stock Issuance | -257 Thousand | 104.45 Million | 112.22 Million | 2.83 Million |
| Other Financing Activities | -1.29 Million | -2.74 Million | - | 116 Thousand |
| Accounts receivables | - | - | - | - |
| Accounts payables | 3.6 Million | -245 Thousand | 798 Thousand | 81 Thousand |
| Inventory | - | - | - | - |
| Other working capital | 4.52 Million | -1.28 Million | -470 Thousand | 236 Thousand |
| Cash at beginning of period | 29.51 Million | 99.99 Million | 1.99 Million | 1.91 Million |
| Cash at end of period | 36.01 Million | 29.9 Million | 99.99 Million | 1.99 Million |
| Capital Expenditure | -1.28 Million | -2.16 Million | -238 Thousand | -15 Thousand |
| Effect of forex changes on cash | -26 Thousand | - | - | - |
| Net cash flow / Change in cash | 6.49 Million | -70.08 Million | 98 Million | 71 Thousand |
| Free Cash Flow | -43.92 Million | -32.28 Million | -14.22 Million | -2.81 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -18.79 Million | -16.48 Million | -19.25 Million | -60.38 Million | -14.46 Million | -13.91 Million |
| Depreciation & Amortization | 200 Thousand | 224 Thousand | 149 Thousand | 536 Thousand | 133 Thousand | 129 Thousand |
| Deferred income taxes | - | - | -186 Thousand | -3.6 Million | -742 Thousand | -768 Thousand |
| Stock-based compensation | 3.56 Million | 3.34 Million | 3.05 Million | 11.61 Million | 3.22 Million | 2.68 Million |
| Change in working capital | 1.97 Million | -3.81 Million | 4.16 Million | 8.13 Million | 1.84 Million | 2.56 Million |
| Other non-cash items | 4.06 Million | 5.71 Million | -300 Thousand | 1.06 Million | 198 Thousand | 195 Thousand |
| Investing Cash Flow | -88.04 Million | 5.85 Million | 20.53 Million | 50.71 Million | 1.51 Million | 19.33 Million |
| Investments in PPE | -137 Thousand | -815 Thousand | -1.15 Million | -1.28 Million | - | -112 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -134.83 Million | -28.33 Million | -16.58 Million | -56.52 Million | -22.98 Million | - |
| Sales/Maturities of investments | 46.92 Million | 35 Million | 38.26 Million | 108.53 Million | 24.5 Million | 19.45 Million |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 123.35 Million | -172 Thousand | -2.01 Million | -1.55 Million | 78 Thousand | 379 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 123.86 Million | -6000.00 | -714 Thousand | -257 Thousand | 78 Thousand | 379 Thousand |
| Other Financing Activities | -510 Thousand | -166 Thousand | -1.29 Million | -1.29 Million | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -943 Thousand | -2.27 Million | 3.17 Million | 3.6 Million | 76 Thousand | -107 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 2.91 Million | -1.54 Million | 995 Thousand | 4.52 Million | 1.76 Million | 2.66 Million |
| Cash at beginning of period | 24.6 Million | 36.01 Million | 29.85 Million | 29.51 Million | 38.48 Million | 27.87 Million |
| Cash at end of period | 46 Million | 24.6 Million | 36.01 Million | 36.01 Million | 30.27 Million | 38.48 Million |
| Capital Expenditure | -137 Thousand | -815 Thousand | -1.15 Million | -1.28 Million | - | -112 Thousand |
| Effect of forex changes on cash | - | - | -3000.00 | -26 Thousand | 12.37 Million | -7.38 Million |
| Net cash flow / Change in cash | 21.39 Million | -11.4 Million | 6.15 Million | 6.49 Million | -8.21 Million | 10.6 Million |
| Free Cash Flow | -14.04 Million | -17.89 Million | -13.51 Million | -43.92 Million | -9.8 Million | -9.22 Million |
300108
SMID
000881
6130
AGGG
CLB